Schedule of Investments
ARK Genomic Revolution ETF
October 31, 2022 (Unaudited)
Investments | Shares | Value | ||||||
COMMON STOCKS–99.3% | ||||||||
Biotechnology - 57.7% | ||||||||
Arcturus Therapeutics Holdings, Inc.*† | 2,088,857 | $ | 36,972,769 | |||||
Beam Therapeutics, Inc.* | 1,970,213 | 86,807,585 | ||||||
CareDx, Inc.*† | 6,144,149 | 122,330,007 | ||||||
Compass Pathways PLC (United Kingdom)*(a) | 1,047,431 | 11,039,923 | ||||||
CRISPR Therapeutics AG (Switzerland)* | 1,603,225 | 83,912,797 | ||||||
Exact Sciences Corp.* | 4,679,848 | 162,765,113 | ||||||
Fate Therapeutics, Inc.* | 4,035,186 | 84,416,091 | ||||||
Incyte Corp.* | 986,181 | 73,312,696 | ||||||
Intellia Therapeutics, Inc.* | 1,720,411 | 90,803,293 | ||||||
Ionis Pharmaceuticals, Inc.* | 3,205,329 | 141,675,542 | ||||||
Iovance Biotherapeutics, Inc.* | 2,218,608 | 20,721,799 | ||||||
Moderna, Inc.* | 156,587 | 23,539,724 | ||||||
Nurix Therapeutics, Inc.* | 2,062,915 | 26,260,908 | ||||||
Organovo Holdings, Inc.* | 174,266 | 285,796 | ||||||
Prime Medicine, Inc.* | 1,256,473 | 23,646,822 | ||||||
Recursion Pharmaceuticals, Inc., Class A* | 3,216,966 | 33,938,991 | ||||||
Regeneron Pharmaceuticals, Inc.* | 35,257 | 26,398,679 | ||||||
Repare Therapeutics, Inc. (Canada)*† | 2,520,030 | 37,951,652 | ||||||
Senti Biosciences, Inc.* | 1,996,698 | 4,632,339 | ||||||
Senti Biosciences, Inc.*,(b) | 243,471 | 508,367 | ||||||
Surface Oncology, Inc.*† | 5,822,877 | 7,220,367 | ||||||
Twist Bioscience Corp.* | 2,352,416 | 77,229,817 | ||||||
Veracyte, Inc.* | 2,332,181 | 46,900,160 | ||||||
Vertex Pharmaceuticals, Inc.* | 150,643 | 47,000,616 | ||||||
Verve Therapeutics, Inc.* | 2,363,325 | 89,097,352 | ||||||
Total Biotechnology | 1,359,369,205 | |||||||
Chemicals - 4.5% | ||||||||
Ginkgo Bioworks Holdings, Inc.* | 38,846,885 | 106,051,996 | ||||||
Electronic Equipment, Instruments & Components - 2.5% | ||||||||
908 Devices, Inc.*† | 3,614,707 | 57,799,165 | ||||||
Health Care Equipment & Supplies - 2.8% | ||||||||
Butterfly Network, Inc.*† | 10,380,379 | 50,863,857 | ||||||
Cerus Corp.* | 3,846,064 | 14,076,594 | ||||||
Total Health Care Equipment & Supplies | 64,940,451 | |||||||
Health Care Providers & Services - 4.8% | ||||||||
Accolade, Inc.*† | 5,664,774 | 61,066,264 | ||||||
Guardant Health, Inc.* | 519,121 | 25,696,489 | ||||||
Invitae Corp.* | 5,286,238 | 13,638,494 | ||||||
Signify Health, Inc., Class A* | 446,356 | 13,046,986 | ||||||
Total Health Care Providers & Services | 113,448,233 | |||||||
Health Care Technology - 9.8% | ||||||||
Schrodinger, Inc.*† | 3,680,541 | 88,222,568 | ||||||
Teladoc Health, Inc.* | 3,632,422 | 107,664,988 | ||||||
Veeva Systems, Inc., Class A* | 219,488 | 36,860,815 | ||||||
Total Health Care Technology | 232,748,371 | |||||||
Life Sciences Tools & Services - 12.7% | ||||||||
10X Genomics, Inc., Class A* | 885,682 | 24,072,837 | ||||||
Adaptive Biotechnologies Corp.*† | 9,087,728 | 70,702,524 | ||||||
Berkeley Lights, Inc.* | 2,866,466 | 6,363,554 | ||||||
Codexis, Inc.*† | 4,091,287 | 22,993,033 | ||||||
Pacific Biosciences of California, Inc.*† | 11,696,488 | 98,718,359 | ||||||
Personalis, Inc.*† | 5,268,887 | 14,067,928 | ||||||
Quantum-Si, Inc.*† | 10,789,890 | 32,693,366 | ||||||
SomaLogic, Inc.* | 9,113,059 | 31,622,315 | ||||||
Total Life Sciences Tools & Services | 301,233,916 | |||||||
Pharmaceuticals - 1.8% | ||||||||
ATAI Life Sciences NV (Germany)* | 5,879,928 | 17,345,788 | ||||||
Pfizer, Inc. | 509,704 | 23,726,721 | ||||||
Total Pharmaceuticals | 41,072,509 | |||||||
Semiconductors & Semiconductor Equipment - 1.0% | ||||||||
NVIDIA Corp. | 180,549 | 24,368,699 | ||||||
Software - 1.7% | ||||||||
UiPath, Inc., Class A* | 3,207,434 | 40,574,040 | ||||||
Total Common Stocks (Cost $6,740,023,773) | 2,341,606,585 | |||||||
MONEY MARKET FUND–0.4% | ||||||||
Dreyfus Government Cash Management Fund, Institutional Shares, 2.91% (c) (Cost $8,728,898) | 8,728,898 | 8,728,898 | ||||||
Total Investments–99.7% (Cost $6,748,752,671) | 2,350,335,483 | |||||||
Other Assets in Excess of Liabilities–0.3% | 7,214,431 | |||||||
Net Assets–100.0% | $ | 2,357,549,914 |
† | Affiliated security |
* | Non-income producing security |
(a) | American Depositary Receipt |
(b) | Restricted security; security may not be publicly sold without registration under the Securities Act of 1933, as amended. As of October 31, 2022, total investments in restricted securities were $508,367 and are classified as Level 2. |
(c) | Rate shown represents annualized 7-day yield as of October 31, 2022. |
Schedule of Investments (continued)
ARK Genomic Revolution ETF
October 31, 2022 (Unaudited)
Affiliated Issuer Transactions
An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities, or a company that is under common ownership or control. Period to date transactions with companies which are or were affiliates are as follows:
Value ($) at 7/31/2022 | Purchases Cost ($) | Sales Proceeds ($) | Net Realized Gain/(Loss) ($) | Net Change in Unrealized Appreciation (Depreciation) ($) | Dividend Income ($) | Capital Gain Distributions ($) | Number of Shares at 10/31/2022 | Value ($) at 10/31/2022 | ||||||||||||||||||||||||||||
Common Stocks — 29.8% | ||||||||||||||||||||||||||||||||||||
Biotechnology — 8.7% | ||||||||||||||||||||||||||||||||||||
Arcturus Therapeutics Holdings, Inc. | ||||||||||||||||||||||||||||||||||||
39,811,175 | 5,421,704 | (8,131,509 | ) | (3,542,651 | ) | 3,414,050 | – | – | 2,088,857 | 36,972,769 | ||||||||||||||||||||||||||
CareDx, Inc. | ||||||||||||||||||||||||||||||||||||
104,441,573 | 54,816,421 | (22,808,828 | ) | 433,141 | (14,552,300 | ) | – | – | 6,144,149 | 122,330,007 | ||||||||||||||||||||||||||
Repare Therapeutics, Inc. | ||||||||||||||||||||||||||||||||||||
34,591,003 | 5,063,160 | (7,722,555 | ) | (3,387,616 | ) | 9,407,660 | – | – | 2,520,030 | 37,951,652 | ||||||||||||||||||||||||||
Surface Oncology, Inc. | ||||||||||||||||||||||||||||||||||||
10,813,242 | 1,259,319 | (1,864,171 | ) | (310,858 | ) | (2,677,165 | ) | – | – | 5,822,877 | 7,220,367 | |||||||||||||||||||||||||
Chemicals — 0.0% | ||||||||||||||||||||||||||||||||||||
Zymergen, Inc. ^ | ||||||||||||||||||||||||||||||||||||
19,213,895 | 2,867,953 | (20,336,476 | ) | (46,330,747 | ) | 44,585,375 | – | – | – | – | ||||||||||||||||||||||||||
Electronic Equipment, Instruments & Components — 2.5% | ||||||||||||||||||||||||||||||||||||
908 Devices, Inc. | ||||||||||||||||||||||||||||||||||||
80,344,058 | 17,093,088 | (14,883,098 | ) | (912,631 | ) | (23,842,252 | ) | – | – | 3,614,707 | 57,799,165 | |||||||||||||||||||||||||
Health Care Equipment & Supplies — 2.2% | ||||||||||||||||||||||||||||||||||||
Butterfly Network, Inc. | ||||||||||||||||||||||||||||||||||||
36,949,002 | 23,594,482 | (12,554,070 | ) | 3,236,958 | (362,515 | ) | – | – | 10,380,379 | 50,863,857 | ||||||||||||||||||||||||||
Health Care Providers & Services — 2.6% | ||||||||||||||||||||||||||||||||||||
Accolade, Inc. | ||||||||||||||||||||||||||||||||||||
56,841,976 | 10,456,393 | (15,809,588 | ) | 6,210,551 | 3,366,932 | – | – | 5,664,774 | 61,066,264 | |||||||||||||||||||||||||||
Health Care Technology — 3.7% | ||||||||||||||||||||||||||||||||||||
Schrodinger, Inc. | ||||||||||||||||||||||||||||||||||||
107,424,667 | 31,588,266 | (22,811,203 | ) | (615,484 | ) | (27,363,678 | ) | – | – | 3,680,541 | 88,222,568 | |||||||||||||||||||||||||
Life Sciences Tools & Services — 10.1% | ||||||||||||||||||||||||||||||||||||
Adaptive Biotechnologies Corp. | ||||||||||||||||||||||||||||||||||||
79,152,238 | 24,186,884 | (17,856,957 | ) | 529,531 | (15,309,172 | ) | – | – | 9,087,728 | 70,702,524 | ||||||||||||||||||||||||||
Codexis, Inc. | ||||||||||||||||||||||||||||||||||||
30,479,069 | 4,468,262 | (6,648,050 | ) | (1,519,535 | ) | (3,786,713 | ) | – | – | 4,091,287 | 22,993,033 | |||||||||||||||||||||||||
Pacific Biosciences of California, Inc. | ||||||||||||||||||||||||||||||||||||
52,499,699 | 16,465,013 | (18,165,406 | ) | (951,643 | ) | 48,870,696 | – | – | 11,696,488 | 98,718,359 | ||||||||||||||||||||||||||
Personalis, Inc. | ||||||||||||||||||||||||||||||||||||
19,984,442 | 4,100,784 | (4,334,247 | ) | (336,109 | ) | (5,346,942 | ) | – | – | 5,268,887 | 14,067,928 | |||||||||||||||||||||||||
Quantum-Si, Inc. | ||||||||||||||||||||||||||||||||||||
37,961,956 | 5,564,210 | (8,184,287 | ) | (2,245,850 | ) | (402,663 | ) | – | – | 10,789,890 | 32,693,366 | |||||||||||||||||||||||||
$ | 710,507,995 | $ | 206,945,939 | $ | (182,110,445 | ) | $ | (49,742,943 | ) | $ | 16,001,313 | $ | – | $ | – | 80,850,594 | $ | 701,601,859 |
^ | As of October 31, 2022, the company was no longer considered to be an affiliated security. |
Fair Value Measurement
The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:
• Level 1 — Quoted prices in active markets for identical assets.
• Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
• Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments).
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
The following is a summary of the valuations as of October 31, 2022, based upon the three levels defined above:
Schedule of Investments (continued)
ARK Genomic Revolution ETF
October 31, 2022 (Unaudited)
ARK Genomic Revolution ETF | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
Assets | ||||||||||||||||
Common Stocks‡ | $ | 2,341,098,218 | $ | 508,367 | $ | – | $ | 2,341,606,585 | ||||||||
Money Market Fund | 8,728,898 | – | – | 8,728,898 | ||||||||||||
Total | $ | 2,349,827,116 | $ | 508,367 | $ | – | $ | 2,350,335,483 | ||||||||
‡ | Please refer to the Schedule of Investments to view securities segregated by industry type. |